Digital therapeutics in hypertension: How to make sustainable lifestyle changes

IF 2.7 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Clinical Hypertension Pub Date : 2024-09-09 DOI:10.1111/jch.14894

Chaoyi Chen MD, Aiting Liu MD, Zhengzhipeng Zhang MD, Jie Chen MD, PhD, Hui Huang MD, PhD

{"title":"Digital therapeutics in hypertension: How to make sustainable lifestyle changes","authors":"Chaoyi Chen MD, Aiting Liu MD, Zhengzhipeng Zhang MD, Jie Chen MD, PhD, Hui Huang MD, PhD","doi":"10.1111/jch.14894","DOIUrl":null,"url":null,"abstract":"<p>Various digital therapeutic products have been validated and approved since 2017. They have demonstrated efficacy and safety as a new therapeutic modality in various disorders or conditions. Hypertension is a common but serious condition that can be prevented or controlled with lifestyle changes and medicines. Although a digital therapeutic in hypertension is validated and approved in Japan, whether digital therapeutics (DTx) can significantly improve sustainable lifestyle changes is still a controversial topic. Most studies did not discuss the long-term gain challenges. In this review, the authors discuss the definition of DTx, and analyze the motivation, engagement and adherence challenges of DTx in hypertension. Some ongoing artificial intelligence (AI)-enabled or cognitive behavioral therapy (CBT)-based digital interventions and behavioral strategies for implementing sustainable lifestyle changes are identified and analyzed. With AI-enabled interventions and behavioral strategies, DTx might be one of the effective approaches to make sustainable lifestyle changes.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.14894","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Various digital therapeutic products have been validated and approved since 2017. They have demonstrated efficacy and safety as a new therapeutic modality in various disorders or conditions. Hypertension is a common but serious condition that can be prevented or controlled with lifestyle changes and medicines. Although a digital therapeutic in hypertension is validated and approved in Japan, whether digital therapeutics (DTx) can significantly improve sustainable lifestyle changes is still a controversial topic. Most studies did not discuss the long-term gain challenges. In this review, the authors discuss the definition of DTx, and analyze the motivation, engagement and adherence challenges of DTx in hypertension. Some ongoing artificial intelligence (AI)-enabled or cognitive behavioral therapy (CBT)-based digital interventions and behavioral strategies for implementing sustainable lifestyle changes are identified and analyzed. With AI-enabled interventions and behavioral strategies, DTx might be one of the effective approaches to make sustainable lifestyle changes.

查看原文本刊更多论文

高血压的数字疗法：如何持续改变生活方式。

自 2017 年以来，各种数字治疗产品已通过验证和批准。它们作为一种新的治疗方式，在各种疾病或病症中都显示出了有效性和安全性。高血压是一种常见但严重的疾病，可以通过改变生活方式和药物来预防或控制。虽然高血压数字疗法已在日本获得验证和批准，但数字疗法（DTx）能否显著改善可持续的生活方式改变仍是一个有争议的话题。大多数研究并未讨论长期收益的挑战。在这篇综述中，作者讨论了 DTx 的定义，并分析了高血压 DTx 在动机、参与度和依从性方面的挑战。作者确定并分析了一些正在进行的人工智能（AI）支持或基于认知行为疗法（CBT）的数字化干预措施和行为策略，以实施可持续的生活方式改变。通过人工智能干预和行为策略，DTx 可能是实现可持续生活方式改变的有效方法之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Hypertension PERIPHERAL VASCULAR DISEASE-

CiteScore

5.80

自引率

7.10%

发文量

191

审稿时长

4-8 weeks

期刊介绍： The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.